The association of hematologic inflammatory markers with atherogenic index in type 2 diabetic retinopathy patients.
BACKGROUND
Atherogenic dyslipidemia is particularly common in people with type 2 diabetes (DM2). Platelets from patients with DM2 have increased reactivity and baseline activation. The aim of the present study is to evaluate the relationship between atherogenic index and hematologic inflammatory markers and to evaluate the relationship between these parameters and associated variables in diabetic retinopathy (DR) patients.


METHODS
The medical records of all patients admitted to the eye clinic between January and December 2014 were evaluated systematically. Laboratory parameters of 278 outpatients with DM2 diagnosed after the age of 30 years and 107 healthy subjects were analyzed.


RESULTS
The DM2 + DR group consisted of 120 patients (47 males and 73 females; mean age 59.8±9.2 years). The DM2 without DR group consisted of 158 patients (59 males and 99 females; mean age 57.3±12.2 years). Mean platelet volume, platelet distribution width (PDW), platelet-lymphocyte (P/L) ratio, triglycerides, and atherogenic index were higher in DM2 patients than in control patients, but there was no difference between the DM2 + DR and the DM2 without DR groups. Only P/L ratio was different in the DM2 + DR patients compared to the DM2 without DR patients. Hemoglobin A1c levels correlated very weakly with the mean platelet volume, PDW, P/L ratio, and the red cell distribution width. The atherogenic index was very weakly correlated with the P/L ratio, PDW, and red cell distribution width.


CONCLUSIONS
Dyslipidemia-induced inflammation contributes to pathological processes that lead to retinopathy in DR patients.
Department of Ophtalmology.
Müberra
M
Akdoğan
Department of Clinical Laboratory, Yüksek ˙Ihtisas Education and Research Hospital, Bursa, Turkey.
Yasemin
Y
Ustundag-Budak
Department of Clinical Laboratory, Yüksek ˙Ihtisas Education and Research Hospital, Bursa, Turkey.
Kagan
K
Huysal
diabetes complications; erythrocyte indices; platelets; triglycerides; type 2 diabetes mellitus
Mod Rheumatol. 2016;26(3):372-6
26403379
Int J Clin Exp Med. 2015 Jul 15;8(7):11420-7
26379958
Lipids Health Dis. 2012 Oct 09;11:132
23046637
Biochim Biophys Acta. 2008 Feb;1780(2):108-15
18035063
J Clin Lipidol. 2010 Mar-Apr;4(2):89-98
21122635
Biochem Med (Zagreb). 2016;26(2):178-93
27346963
Am J Kidney Dis. 2003 Jul;42(1):53-61
12830456
Kardiol Pol. 2013;71(9):931-6
24065422
Pan Afr Med J. 2014 May 12;18:42
25368731
Prim Care Diabetes. 2015 Jun;9(3):226-30
25249479
Biochem Med (Zagreb). 2012;22(1):49-62
22384519
Int Immunopharmacol. 2016 Jul;36:94-99
27111516
Clin Biochem. 2001 Oct;34(7):583-8
11738396
Acta Diabetol. 2006 Dec;43(4):109-13
17211560
Int J Clin Exp Med. 2014 Dec 15;7(12):5737-43
25664100
Thromb Haemost. 1992 May 4;67(5):567-71
1519216
Eye Vis (Lond). 2015 Sep 30;2:17
26605370
Int J Clin Exp Med. 2014 Aug 15;7(8):2292-7
25232423
Cardiovasc Diabetol. 2016 Mar 31;15:52
27036108
Ann Intern Med. 2006 Aug 15;145(4):247-54
16908915
Diabetes Res Clin Pract. 2011 Dec;94(3):311-21
22079683
Clin Exp Ophthalmol. 2016 May;44(4):260-77
26716602
Turk J Med Sci. 2014;44(1):121-5
25558571
Metabolism. 2000 Jul;49(7):942-9
10910008
Biochem Med (Zagreb). 2015;25(1):97-102
25672473
Int J Biochem Cell Biol. 2007;39(9):1673-84
17540609
Dis Markers. 2010;29(1):55-61
20826918
Hemodial Int. 2013 Oct;17(4):668-9
23763539
Anadolu Kardiyol Derg. 2006 Dec;6(4):314-21
17162275
Clin Appl Thromb Hemost. 2007 Oct;13(4):391-7
17911190
Clin Appl Thromb Hemost. 2014 Jul;20(5):473-7
23344996
Thromb Res. 2010 Sep;126(3):e225-31
20637495